ES2192194T3 - Tratamiento medico que usa hormonas tiroideas. - Google Patents

Tratamiento medico que usa hormonas tiroideas.

Info

Publication number
ES2192194T3
ES2192194T3 ES94921305T ES94921305T ES2192194T3 ES 2192194 T3 ES2192194 T3 ES 2192194T3 ES 94921305 T ES94921305 T ES 94921305T ES 94921305 T ES94921305 T ES 94921305T ES 2192194 T3 ES2192194 T3 ES 2192194T3
Authority
ES
Spain
Prior art keywords
treatment
medical treatment
thyroid hormones
thyroid hormone
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94921305T
Other languages
English (en)
Inventor
Gilbert Mayor
Alecy Louis D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
Abbott GmbH and Co KG
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG, University of Michigan System, University of Michigan Ann Arbor filed Critical Abbott GmbH and Co KG
Application granted granted Critical
Publication of ES2192194T3 publication Critical patent/ES2192194T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA ISQUEMIA DEL SISTEMA NERVIOSO CENTRAL SE PREVIENE O MINIMIZA EN PACIENTES QUE HAYAN SUFRIDO UN PROCESO AGUDO ADMINISTRANDOLES UNA CANTIDAD PREVENTIVA DE HORMONA TIROIDEA TAL COMO LEVOTIROXINA, LIOTIRONINA, L-3,3`,5`-TRIYODOTIRONINA O L-3,5 DIYODOTIRONINA, PREFERIBLEMENTE EN FORMA DE SUS SALES DE SODIO. SE PUEDE OFRECER UNA DOSIS INICIAL EN FORMA DE PILDORA MAYOR DE LO NORMAL DE HORMONA TIROIDEA ANTES DE LA INICIACION DE LA ADMINISTRACION CONTINUA. EL TRATAMIENTO ESTA PARTICULARMENTE INDICADO PARA EL TRATAMIENTO DE LA ISQUEMIA CEREBRAL QUE SIGUE AL PARO CARDIACO.
ES94921305T 1993-06-22 1994-06-22 Tratamiento medico que usa hormonas tiroideas. Expired - Lifetime ES2192194T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7980593A 1993-06-22 1993-06-22

Publications (1)

Publication Number Publication Date
ES2192194T3 true ES2192194T3 (es) 2003-10-01

Family

ID=22152935

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94921305T Expired - Lifetime ES2192194T3 (es) 1993-06-22 1994-06-22 Tratamiento medico que usa hormonas tiroideas.

Country Status (11)

Country Link
US (1) US5571840A (es)
EP (1) EP0751769B1 (es)
JP (1) JPH09503485A (es)
KR (1) KR100348117B1 (es)
AT (1) ATE230986T1 (es)
AU (1) AU680669B2 (es)
CA (1) CA2165822A1 (es)
DE (1) DE69432027T2 (es)
DK (1) DK0751769T3 (es)
ES (1) ES2192194T3 (es)
WO (1) WO1995000135A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US6702265B1 (en) 1999-02-10 2004-03-09 Erik Zapletal Balanced suspension system
WO2000064448A1 (en) 1999-04-27 2000-11-02 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
ATE312606T1 (de) 1999-10-29 2005-12-15 Orion Corp Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
AU2001247759A1 (en) * 2000-03-24 2001-10-08 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US20020193440A1 (en) * 2001-02-20 2002-12-19 Ritter Steven C. Liothyronine sodium and levothyroxine sodium combination
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20040156893A1 (en) * 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
JP2007505837A (ja) 2003-09-15 2007-03-15 オードウェイ リサーチ インスティテュート 甲状腺ホルモンアナログおよび新脈管形成における使用の方法
EP1689383B1 (en) * 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
AU2005284879B2 (en) * 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
US20060128797A1 (en) * 2004-12-15 2006-06-15 Yanming Wang Method and composition for resuscitation
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
JP2010513526A (ja) 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
EP3305281A1 (en) * 2009-05-15 2018-04-11 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
CA2858721C (en) 2011-12-11 2021-03-16 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
WO2015074050A1 (en) 2013-11-18 2015-05-21 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
WO2017003125A1 (ko) * 2015-06-29 2017-01-05 한양대학교 산학협력단 트리요오드티로닌, 티록신 또는 이의 염을 포함하는 뇌신경계 질환의 예방, 개선 또는 치료용 조성물
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
EP3634528B1 (en) 2017-06-07 2023-06-07 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
US11511103B2 (en) 2017-11-13 2022-11-29 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
EP3746149B1 (en) 2018-02-01 2025-08-06 Shifamed Holdings, LLC Intravascular blood pumps
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020028537A1 (en) 2018-07-31 2020-02-06 Shifamed Holdings, Llc Intravascaular blood pumps and methods of use
WO2020073047A1 (en) 2018-10-05 2020-04-09 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
ES2942441T3 (es) * 2019-01-09 2023-06-01 Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A L-triyodotironina (T3) para el uso en la limitación de la obstrucción microvascular
WO2021011473A1 (en) 2019-07-12 2021-01-21 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US12465748B2 (en) 2019-08-07 2025-11-11 Supira Medical, Inc. Catheter blood pumps and collapsible pump housings
WO2021062260A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
EP4501393A3 (en) 2019-09-25 2025-04-09 Shifamed Holdings, LLC Catheter blood pumps and collapsible pump housings
EP4077947A4 (en) 2019-12-19 2024-01-10 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS, MOTORS AND FLUID CONTROL
GR1010068B (el) * 2020-04-21 2021-09-01 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE" Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237435B (it) * 1989-12-14 1993-06-04 Farmaco attivo nel ripristino della plasticita' neuronale.
WO1991011181A1 (en) * 1990-02-05 1991-08-08 British Technology Group (Usa) Incorporated Thyroid hormone cardiac treatment
US5158978A (en) * 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise

Also Published As

Publication number Publication date
CA2165822A1 (en) 1995-01-05
US5571840A (en) 1996-11-05
KR100348117B1 (ko) 2002-12-02
EP0751769B1 (en) 2003-01-15
ATE230986T1 (de) 2003-02-15
JPH09503485A (ja) 1997-04-08
EP0751769A1 (en) 1997-01-08
DE69432027T2 (de) 2003-10-09
DE69432027D1 (de) 2003-02-20
AU7208094A (en) 1995-01-17
WO1995000135A1 (en) 1995-01-05
DK0751769T3 (da) 2003-04-07
EP0751769A4 (en) 1998-05-27
AU680669B2 (en) 1997-08-07

Similar Documents

Publication Publication Date Title
ES2122700T3 (es) Aparato de administracion por electrotransporte.
ES2156124T3 (es) Formulaciones que contienen acido hialuronico.
ES2153338T1 (es) Dosificacion mejorada de dosis multiples de medicamentos.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
EP0751769A4 (en) MEDICAL TREATMENT USING THYROID HORMONES
DK0586621T3 (da) Linsidomin til behandling af erektile dysfunktioner
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
MX9303969A (es) Uso de fosfonatos y farmacos antiinflamatorios no esteroidales para el tratamiento de artritis.
ES2082288T3 (es) Composiciones terapeuticas para administracion intranasal de ketorolaco.
EP1064000A4 (en) VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS
PT95002A (pt) Metodo e dispositivo para administracao transdermica de dexmedetomidina
ES2098496T3 (es) Forma medicamentosa aplicable por via peroral para el tratamiento de estados de insuficiencia de dopamina en el sistema nervioso central.
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
ATE121627T1 (de) Verminderung oder verhütung der von arzneimitteln verursachten hautreizung.
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
CO5540323A2 (es) Administracion oral de hormona paratiroides y calcitonina
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
SMARR et al. Experiences with Marsilid with report of one death
Mckinney Jr et al. Depression with the use of alpha-methyldopa
VILKIN Comparative chemotherapeutic trial in treatment of chronic borderline patients
MX9400040A (es) Composiciones para tratar trastornos respiratorios.
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
ES2139013T3 (es) Compuestos de fosfonato que contienen nitrogeno cuaternario para tratar el metabolismo anormal del calcio y fosfato.